American Association for Cancer Research
crc-22-0263-s01.pdf (367.78 kB)

Table S1 from Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Download (367.78 kB)
journal contribution
posted on 2023-04-04, 02:00 authored by Alexa C. Glencer, Phoebe N. Miller, Heather Greenwood, Cristian K. Maldonado Rodas, Rita Freimanis, Amrita Basu, Rita A. Mukhtar, Case Brabham, Paul Kim, E. Shelley Hwang, Jennifer M. Rosenbluth, Gillian L. Hirst, Michael J. Campbell, Alexander D. Borowsky, Laura J. Esserman

Supplementary Table 1


HHS | NIH | National Cancer Institute (NCI)



A retrospective analysis of 71 patients with DCIS who did not undergo upfront surgery demonstrated that breast MRI features after short-term exposure to endocrine therapy identify those at high (68.2%), intermediate (20.0%), and low risk (8.7%) of IDC. With 7.4 years mean follow-up, 52.1% of patients remain on active surveillance. A period of active surveillance offers the opportunity to risk-stratify DCIS lesions and guide decisions for operative management.